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Amyotrophic lateral sclerosis (ALS) is a progressive adult-onset neurodegenerative
disease, that affects cortical, bulbar and spinal motor neurons, and it is considered
a proteinopathy, in which pathological proteins (SOD1, TDP-43, and FUS) may
accumulate and interfere with neuronal functions eventually leading to cell death. These
proteins can be released from cells and transported in the body fluids by extracellular
vesicles (EVs). EVs are spherical vesicles, which are classified mainly in microvesicles
(MVs) and exosomes (EXOs) based on their biogenesis, size and surface markers. In this
study we characterized MVs and EXOs isolated from plasma of sporadic ALS patients
and healthy controls and determined their number, size and SOD1, TDP-43, and FUS
protein composition. No variation was found in the number of EVs between ALS patients
and controls. However, the mean size both for MVs and for EXOs resulted increased in
ALS patients compared to controls. MVs derived from ALS patients were enriched in
SOD1, TDP-43, phospho-TDP-43, and FUS proteins compared to CTRLs. SOD1 was
generally more concentrated in EXOs than in MVs, while TDP-43 and FUS protein levels
were slightly higher in MVs than in EXOs. We demonstrated that MVs and EXOs size
were increased in ALS patients compared to controls and that MVs of ALS patients
were enriched with toxic proteins compared to CTRLs. EXOs did not show any protein
changes. These data may suggest that MVs can transport toxic proteins and might play
a role in prion-like propagation of ALS disease.
Keywords: amyotrophic lateral sclerosis, proteinopathy, extracellular vesicles, microvesicles, exosomes, SOD-1,
TDP-43, FUS
Abbreviations: ALS, amyotrophic lateral sclerosis; EVs, extracellular vesicles; EXOs, exosomes; MVs, microvesicles; SGs,
Stress Granules.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a progressive adult-
onset neurodegenerative disease that primarily affects upper and
lower motor neurons (Al-Chalabi et al., 2016). The disease is
considered a proteinopathy, since spinal cord histology of ALS
patients reveals abnormal accumulations of protein aggregates
in motor neurons and neural accessory cells (Polymenidou and
Cleveland, 2011). These aggregates (especially SOD1, TDP-43,
FUS) originate from the accumulation of non-natively folded
proteins that can propagate in a way similar to prion proteins
(self-seeding), although neuronal cells are not infected with
prions (Cereda et al., 2006, 2013; Diaz-Espinoza and Soto, 2010;
Polymenidou and Cleveland, 2011; Pansarasa et al., 2018). This
process could be mediated through release and uptake of protein
aggregates or via extracellular vesicles (EVs) (Grad et al., 2014).
Extracellular vesicles (EVs) have become an intriguing field in the
study of neurodegenerative diseases. EVs are spherical vesicles
classified mainly for size and biological functions in microvesicles
(MVs) and exosomes (EXOs). MVs and EXOs are vesicles of
100–1,000 nm and 30–140 nm in diameter, respectively. Various
studies have described both classes and although size is the
simplest method to distinguish EXOs from MVs, there is a
subpopulation of MVs which overlap in dimension with EXOs
and viceversa. MVs are shed by budding of all cells plasma
membrane and they express membrane receptors on their surface
(Thery et al., 2006; Raposo and Stoorvogel, 2013; Cocucci and
Meldolesi, 2015). MVs production is observed in a variety of
cells in a resting state, but can be significantly elevated under
various stimulations, including increased [Ca2+], cellular stress
and immune system response, all mechanisms observed in ALS
(Akers et al., 2013). EXOs instead are released by exocytosis of
multivesicular bodies (MVBs), which can degradate or can fuse
with the plasma membrane (Raposo and Stoorvogel, 2013).
Autophagy malfunction is often linked to EXOs secretion and
it is well known that loss of basal autophagy, as a degradative
pathway of proteins, is a cause of neurodegeneration of ALS
(Baixauli et al., 2014). In ALS EVs are described in the
release and uptake of misfolded/aggregated proteins like SOD1,
TDP-43 and FUS and most of the evidence in the literature
regards EXOs from cell cultures, but not MVs. The loading
mechanism of EXOs is controlled by different pathways, like
the endosomal sorting complexes (ESCRT) machinery, required
for the sorting of ubiquitinated membrane proteins (Moreno-
Gonzalo et al., 2014). It was observed that the presence and
the propagation of mutated SOD1 (mutSOD1) and wild type
SOD1 (WTSOD1) from an in vitro motor neuron-like cell
model, NSC-34, can occur via EXOs (Gomes et al., 2007; Munch
and Bertolotti, 2011; Basso et al., 2013; Grad et al., 2014).
EXOs release is enhanced in astrocytes expressing mutSOD1
and it has been suggested that the process may serve to
eliminate protein aggregates from cells (Urushitani et al., 2008).
It was demonstrated that mutSOD1 oligomers accumulate in
the endoplasmic reticulum–Golgi compartments of the endocytic
pathway prior to their secretion (Pinto et al., 2017). Similar
to some mutSOD1 species, TDP-43 aggregates, isolated from
the brains of ALS and FTLD (frontotemporal lobar dementia)
patients, self-propagate in the ubiquitinated and phosphorylated
form through EXOs in cultured human neuroblastoma cells
(Nonaka et al., 2013; Iguchi et al., 2016) also demonstrated
that exposure of Neuro2a cells to EXOs from an ALS brain,
but not from a control brain, caused cytoplasmic redistribution
of TDP-43, an important marker of proteinopathy. TDP-43
is transported by cerebrospinal fluid (CSF) derived EXOs of
ALS patients and healthy donors and there is no differences in
TDP-43 protein level between the two groups (Feneberg et al.,
2014). So far, no evidence of the presence of FUS in MVs
and EXOs has been reported. Primarily, in this study we have
investigated whether circulating MVs and EXOs derived from
plasma of sporadic ALS patients exhibit different concentrations
and size compared to healthy controls. In addition, we also
examined the loading difference of pathological proteins between
MVs and EXOs of sporadic ALS patients and CTRLs in
order to understand EVs contribution in pathological proteins
clearance.
MATERIALS AND METHODS
Subjects
ALS diagnosis was made according to the revised El Escorial
Criteria (Brooks et al., 2000) at IRCCS Mondino Foundation
(Pavia). Patients with concomitant comorbidity (thyroiditis,
cancer, etc.) were excluded. Blood from 30 sporadic ALS patients
(SALS in the text they will be called ALS patients) was collected
(mean age: 71.3 ± SD 7.5). ALS individuals harboring mutations
in SOD1, FUS/TLS, TARDBP, C9ORF72, and ANG genes were
excluded. Subjects participating in the study signed an informed
consent (Protocol n. 375/04 – version 07/01/2004) in accordance
with the Declaration of Helsinki. See Table 1 for demographic
and clinical characteristics. Thirty sex- and age-matched healthy
volunteers free from any pharmacological treatment were
recruited at the Immunohematological and Transfusional Service
and Centre of Transplantation Immunology IRCCS Foundation
“San Matteo” (Pavia, Italy) and used as non-neurological controls
(CTRLs) after signature of the informed consent in accordance
with the Declaration of Helsinki. Moreover, healthy controls
were not affected by any neurological or psychiatric condition,
nor were taking psychoactive drugs. This study protocol from
patients and controls was approved by the Ethical Committee of
the IRCCS Mondino Foundation (Pavia, Italy).
Isolation of MVs and EXOs
Venous blood (7 mL) was collected in sodium citrate tubes
from all patients and controls. Within 1 h it was centrifugated
at 1,000 g for 15 min to separate plasma, followed by an
additional centrifugation at 1,600 g for 20 min to remove
platelets. Platelet-free plasma was then transferred to a new tube
and snap frozen at −80◦C. Prior to the analysis, platelet-free
plasma was thawed on ice and it was centrifuged at 20,000 g
for 1 h with Centrifuge 5427 R (Eppendorf, Italy). The pellet
was washed with 0.22 µm filtered PBS and centrifuged for 1 h
at 20,000 g. The pellet was then processed for MVs analysis.
The supernatant of MVs was filtered through a 0.2 µm filter
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TABLE 1 | List of patients and clinical features.
Number Gender Age of
onset, year
Site of
onset
ALSFRSr_ Nanosight WB
1 M 67 S 35 x x
2 F 56 S 43 x x
3 M 85 B 44 x x
4 F 79 S 32 x
5 F 59 S 32 x
6 M 65 S 41 x x
7 M 61 S 32 x x
8 M 62 S 29 x x
9 M 78 S 41 x
10 M 68 S 48 x
11 F 70 S 38 x x
12 M 64 B 39 x
13 F 67 S 33 x x
14 M 60 B 45 x x
15 F 65 S 42 x x
16 F 73 B 23 x
17 M 82 S 41 x x
18 F 63 S 27 x x
19 M 52 S 40 x x
20 M 69 S 42 x
21 M 70 S 40 x x
22 F 73 S 42 x x
23 F 63 B 34 x
24 F 67 S 44 x x
25 F 74 S 24 x x
26 F 67 S 22 x x
27 F 67 S 42 x x
28 F 78 B 26 x x
29 M 75 B 27 x
30 M 80 B 41 x
M, male; F, female; S, spinal; B, bulbar; ALSFRS, ALS Functional Rating Scale;
WB, Western Blot. Samples used for Nanosight and for Western blot are marked
by an x.
and spun in an Optima MAX-TL Ultracentrifuge at 100,000 g
for 1 h at 4◦C. After ultracentrifugation, the supernatant
was removed and the EXOs pellet was washed with 1 mL
of filtered PBS at 100,000 g for 1 h at 4◦C (Thery et al.,
2006). The obtained EXOs pellet was processed for analysis.
Western Blot analysis for MVs markers (Annexin V-Abcam,
Inc., United States- and Integrin α2β Santa Cruz Biotechnology,
Inc., United States) and for EXOs markers (Alix-Abcam, Inc.,
United States and Flotillin-BD Biosciences, United States) and
Nanoparticle-tracking analysis (NTA) were run to confirm MVs
and EXOs purity (Figure 1).
Nanoparticle-Tracking Analysis (NTA) of
MVs and EXOs
Twenty patients and twenty CTRLs were analysed by NTA using
a NS300 instrument (NanoSight, Amesbury, United Kingdom) in
order to detect size and concentration of MVs and EXOs. For a
more accurate detection, MVs and EXOs samples were diluted
with PBS to an optimal concentration (107–109 particles/ml).
After dilution, 1 mL of diluted sample was loaded on the machine
and read in a rate of about 30 frames/s. Particle movement videos
(60 s/video) were recorded three times per test and size and mean
concentration were analysed by the NTA software (version 2.2,
NanoSight). The results of NTA were presented as the mean of
the three tests.
Transmission Electron Microscopy (TEM)
Transmission electron microscopy was used to study the
morphology of MVs and EXOs. For TEM, 40 µL of vesicle
suspension were placed on a carbon-coated EM grid, and 0.4 µL
of 25% glutaraldehyde was added. Vesicles were then allowed to
settle onto the grid overnight at 4◦C. Grids were then blotted on
filter paper and stained for 30 s with 2% uranyl acetate. After
further blotting and drying, samples were directly observed on
a Tecnai 10 TEM (FEI). Images were captured with a Megaview
G2 camera and processed with iTEM and Adobe Photoshop
software.
Protein Extraction of MVs and EXOs
MVs and EXOs pellet were lysed in cold Radio-
Immunoprecipitation Assay (RIPA) buffer containing a mixture
of phosphatase and protease inhibitors (Sigma-Aldrich, Italy).
They were incubated for 20 min in ice and centrifuged at 16,000 g
for 5 min at 4◦C. The supernatant was transferred to a fresh
tube and protein concentration was determined by BCA assay
(Sigma-Aldrich, Italy). The insoluble fraction was processed as
described in FRA section.
Western Blot Analysis
An amount of 30 µg of MVs and EXOs lysates were loaded
on SDS 12.5% polyacrylamide gels with a Mini-PROTEAN R©
Tetra Vertical Electrophoresis Cell (BioRad, Italy) transferred
to a nitrocellulose membrane (BioRad, Italy), using a semi-dry
transfer apparatus (Trans-blot, BioRad, Italy) and blocked
with 5% non-fat dry milk in Tween-20 Tris-Buffered Saline
solution (TBS-T) (blocking solution) for 1 h. Membranes
were incubated overnight with a mouse monoclonal primary
antibody anti-TDP-43 (Proteintech, Inc., United States),
which recognizes the full-length protein as well as all post-
translationally modified (phosphorylated and glycosylated
forms) and truncated forms in multiple applications in blocking
solution. Membranes were then incubated for 1 h at room
temperature with donkey anti-mouse secondary peroxidase-
conjugated antibody (GE Healthcare, United Kingdom).
Bands were visualized using an enhanced chemiluminescence
detection kit (ECL Advance, Ge Healthcare, United Kingdom).
For subsequent immunoreactions, primary and secondary
antibodies were removed from the membrane with stripping
solution (100 mM Glycine, 0.1% NP-40, 1% SDS pH 2.2)
incubated for 20 min. Membranes were then washed with
TBST and processed, as previously described with SOD1-
DSE2-3H1 antibody (kindly given by Prof. Neil R. Cashman),
SOD1 antibody (Santa Cruz Biotechnology, United States),
which recognizes all SOD1 independently from its subtype,
and FUS antibody (GeneTex, United States). To confirm
the purity of MVs and EXOs preparations, anti-Annexin V
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FIGURE 1 | Analysis of dimension and markers of MVs and EXOs from plasma of healthy controls. (A) Nanoparticle distribution by NTA confirmed the purity of MVs
(orange line-mode = 142.8 ± 6.0 nm) and EXOs (red line-mode = 96.7 ± 4.7 nm); (B) Representative images obtained by transmission electron microscopy (TEM) of
MVs (two MVs of about 150 nm) and EXOs (two EXOs of about 90 nm) from plasma of a healthy control (Scale bar: 100 nm); (C) Representative dot plot of the
concentration of plasma derived MVs and EXOs of 20 healthy individuals showed no variation between the two groups; (D) Western Blot of MVs and EXOs markers
in MVs and EXOs samples showed the presence of Annexin V and Integrin α2β only in MVs pellet and Alix and Flotillin-1 especially in the EXOs fraction.
(Santa Cruz Biotechnology, Inc., United States) or Anti-Alix
(Abcam, Inc., United States) antibodies were used, respectively.
Densitometric analysis of the bands was performed using
ImageJ software (National Institutes of Health, United States).
Densitometric assessment in arbitrary units was carried out in
each EVs fraction.
Filter Retardation Assay (FRA)
Twelve micrograms of protein extracts (quantified used the
BCA assay as described above) were prepared in a volume of
100 µL of RIPA buffer and loaded onto 0.2 µm cellulose acetate
membrane (Whatman, GE Healthcare, United Kingdom) and
filtered through a Bio-Dot SF Microfiltration Apparatus (BioRad,
Italy). Slot-blots were probed as described for WB to detect
retained SOD1 insoluble species. Densitometric optical analysis
of slot-blots and their relative ponceau (used for loading control)
was performed and represented as mean± SEM.
Statistical Analysis
Results of independent experiments were expressed as
mean ± SEM. Statistical tests were performed using a GraphPad
Prism program. T test and one-way ANOVA with Bonferroni’s
multiple comparison test was performed. A p < 0.05 was
considered statistically significant.
RESULTS
Microvesicles and Exosomes Sizes Are
Enhanced in Plasma of ALS Patients
MVs and EXOs were purified from plasma of 20 healthy donors
by differential centrifugation and filtration protocol (Thery et al.,
2006), and NTA was used to identify their dimension and
concentration. As shown in Figure 1A, the mode size of EXOs
and MVs was 96.7 nm ± SD 4.7 nm and 142.8 nm ± SD
6.0 nm, respectively. Different size of MVs and of EXOs were
also confirmed by TEM (Figure 1B). Plasma derived MVs and
EXOs from 20 healthy controls showed the same concentration
(4.14× 1010 particles/mL± 1.18× 1010 particles/ml for MVs and
3.05 × 1010 particles/mL ± 7.4 × 109 particles/mL) (Figure 1C).
According to the literature, purity of MVs and EXOs was tested
by detection of classical MVs and EXOs enriched markers by WB
(Hugel et al., 2005; Baietti et al., 2012; Lötvall et al., 2014). As
shown in Figure 1D, MVs were recognized by Annexin V and
Integrin α2β, whilst EXOs were enriched in Alix and Flotillin 1.
Once confirmed the purity of MVs and EXOs pellets, we also
performed NTA (Nanoparticle Tracking Analysis) on MVs and
EXOs derived from plasma of ALS patients to check the difference
in concentrations and sizes compared to controls. MVs and EXOs
concentrations did not differ between ALS patients and healthy
controls (for MVs CTRLs 4.14 × 1010 ± 1.18 × 1010 vs. ALS
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3.72 × 1010 ± 5.44 × 109 particles/mL and for EXOs CTRLs
3.05 × 1010 ± 7.40 × 109 vs. ALS 3.35 × 1010 ± 4.96 × 109
particles/mL) (Figures 2A,B). Surprisingly, mean dimension
resulted increased in ALS patients compared to controls, both for
MVs (CTRLs 148.4 nm± 5.818 nm vs. ALS 192.0 nm± 12.13 nm,
∗∗p < 0.01) (Figure 3A) and for EXOs (CTRL 117.0 nm ± SD
4.127 nm vs. ALS 162.1 nm ± SD 7.604 nm, ∗∗∗p < 0.001)
(Figure 3B). On average, MVs and EXOs derived from plasma
of ALS patients were about 40 nm bigger than the CTRLs
in both cases. The difference in size between healthy donors
and ALS MVs and EXOs distribution is also clearly shown in
Figures 3C,D. These data were confirmed by TEM (Figure 3E).
MVs and EXOs From ALS Patients Are
Enriched With SOD-1, TDP-43, and FUS
Proteins
We investigated if ALS pathological proteins such as SOD1, TDP-
43, and FUS in EVs differ between EVs from plasma of ALS
patients compared to age- and sex-matched healthy controls
(each group was composed of 30 individuals). Annexin V and
Alix were used as common markers for MVs and EXOs fraction.
We used two antibodies to detect SOD1: a monoclonal one
(SOD1-DSE2-3H1) and a polyclonal antibody (SOD1). SOD1
(evaluated using the specific DSE2-3H1 antibody) was detected
in both EVs types and in both ALS and healthy CTRL SOD1.
Overall SOD1 was more concentrated in EXOs than in MVs
(p < 0.001). In EXOs we did not find differences in SOD1
concentration between ALS patients and healthy CTRL; while, in
MVs derived from ALS patients SOD1 protein levels were higher
than CTRLs (p < 0.05) (Figure 4B). The polyclonal antibody
against SOD1 did not recognize any protein in the soluble
fraction of MVs and EXOs from plasma of either ALS or healthy
controls (Figure 4A). However, by analyzing the aggregated
SOD1 using filter retardation assay (FRA), we found SOD1 in the
insoluble fraction (Figure 4C). SOD1 reactive species, retained
on the cellulose acetate membrane, were similar in ALS and
CTRL groups either in MVs or in EXOs, even though EXOs
contained more insoluble SOD1 species than MVs (Figure 4D).
The monoclonal antibody against TDP-43 recognized two bands
at 43 and 45 KDa, the intact protein and its phosphorylated
isoform. Interestingly, TDP-43 and its phosphorylated (p-TDP-
43) form were slightly higher in MVs than EXOs derived from
ALS patients (p< 0.001). Further, TDP-43 and mostly p-TDP-43
levels were statistically higher in MVs derived from ALS patients
than from CTRLs (p< 0.05, p< 0.001) (Figure 4B). FUS protein
followed the trend observed for p-TDP-43. In fact, FUS protein
levels were slightly higher in MVs than in EXOs (p < 0.001) and
differentially concentrated in MVs of ALS patients compared to
controls (p< 0.05).
DISCUSSION
Microvesicles (MVs) and exosomes (EXOs) are EVs of distinct
dimension and biological functions. This study is the first one
that evaluated the dimension, the concentration and ALS-related
protein cargo of MVs and EXOs from plasma of ALS patients
compared to healthy controls. Plasma derived MVs and EXOs
were separated by differential centrifugation and filtration. This
method led to the isolation of MVs and EXOs with an overlap of
dimension as described in the literature (Gardiner et al., 2016).
However, evidence from imaging, NTA and western blotting
indicated that our protocol separated and effectively minimized
contamination of MVs in EXOs and viceversa. Plasma derived
MVs and EXOs from ALS patients were significantly bigger than
healthy controls. In ALS EVs were described to be involved in the
release and uptake of pathological proteins only in cell cultures,
but not in human biofluids (Gomes et al., 2007; Urushitani et al.,
2008; Munch and Bertolotti, 2011; Basso et al., 2013; Nonaka
et al., 2013; Feneberg et al., 2014; Grad et al., 2014; Iguchi et al.,
2016; Pinto et al., 2017).
Previous studies reported that EVs derived from cultured
PC12 cells had a larger average size in electron microscopy
FIGURE 2 | MVs and EXOs abundance do not differ between ALS patients and controls. NTA was performed on MVs and EXOs extracted from plasma of healthy
controls and ALS patients (n = 20 per group). When averaged, the concentration of MVs (A) and EXOs (B) was not significantly different between the two groups (for
MVs CTRLs 4.14 ×1010± 1.18 × 1010 vs. ALS 3.72 × 1010 ± 5.44 × 109 particles/mL and for EXOs CTRLs 3.05 ×1010 ± 7.40 × 109 vs. ALS
3.35 × 1010 ± 4.96 × 109 particles/mL).
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FIGURE 3 | Mean diameter of MVs and of EXOs from ALS patients were significantly higher than healthy donors (CTRLs). Dot plot of the mean size of plasma
derived MVs (A) and EXOs (B) of 20 ALS patients and 20 healthy individuals are shown (t-test, ∗∗p < 0.01, ∗∗∗∗p < 0.0001). (C,D) NTA profiles overlay between
ALS MVs (red line-mean = 234.3 ± 1.7 nm) and CTRL MVs (orange line-mean = 174.7 ± 1.8 nm) and ALS EXOs (red line-mean = 150.3 ± 3.5 nm) and CTRL EXOs
(orange line-mean = 103.7 ± 0.7 nm). The peak size represents the mode; (E) Representative images obtained by transmission electron microscopy (TEM) of MVs
and EXOs of an ALS patient (ALS) and a healthy control (Scale bar: 100 nm). Images were cropped and original images are shown in Supplementary Figure 1.
Diameter of MVs and of EXOs from ALS patients were significantly higher than healthy donors (Supplementary Figures 1A,B for MVs; Supplementary Figures 1C,D
for EXOs). Full figures are represented in Supplementary Figure 1.
(EM) images and this was due to the greater numbers of
vesicular transporters or neurotransmitters (Colliver et al., 2000;
Daniels et al., 2006). Significant increased diameter suggests that
ALS EVs are enriched by macromolecules in response to the
disease process (Needham and Nunn, 1990). In fact, we found
a significant enrichment of SOD1, TDP-43, p-TDP-43, and FUS
in MVs of ALS patients compared to CTRLs. While in MVs
the enhancement of protein cargo can justify the enhancement
in size, this cannot be said for EXOs, which do not have the
same protein variation compared to healthy control. Probably, in
physiological conditions EXOs are the principal way to scavenge
unfolded proteins, while during the disease when the bulk of
the pathological proteins is largely increased, the MVs system is
activated. We found an enhanced level of pathological proteins
in plasma derived MVs from ALS patients compared to controls.
The enhanced size of EXOs could be caused by a selective
enrichment with other biomolecules such as lipids, other proteins
and RNAs (Raposo and Stoorvogel, 2013). Studies of their cargo
could confirm the different regulation of the two classes of EVs
and their selectivity in the transport of macromolecules.
In addition, we found that SOD1 was generally enriched
in EXOs compared to MVs, while p-TDP-43 and FUS
were slightly more concentrated in MVs than in EXOs.
This result underlines a selectivity of MVs and EXOs in
protein cargo transport. mutSOD1 is consistently associated
with JUNQ (juxtanuclear quality control compartment)-like
inclusions, microtubule dependent inclusions enriched in
ubiquitilated proteins, proteasome subunits and chaperones
such as Hsp70 (Kaganovich et al., 2008). Maturation of late
endosomes is governed by microtubules movement toward
the cell center in a dynein-dependent fashion, so this might
explain SOD1 enrichment in EXOs compared to MVs (Martin-
Cofreces et al., 2014). Farrawell et al. demonstrated that
TDP-43 and FUS can form JUNQ-like inclusions, but also
microtubule-independent inclusions, called insoluble protein
deposit (IPOD) compartment. These inclusions (differently from
SOD1 inclusions) can be formed slowly and can incorporate large
complexes, like mRNA or DNA, and they might migrate in stress
granule (SGs) formations (Farrawell et al., 2015). Removal of SGs
is also regulated by autophagy pathways (Buchan et al., 2013)
and insufficient digestion of damaged molecules might promote
an alternative release of these molecules through EXOs. On the
other hand, MVs production can be significantly elevated under
various stressor stimulations, including increased concentration
of Ca2+, cellular stress and immune system response (Akers
et al., 2013), events that can be caused by SOD1, TDP-43, and
FUS aggregation in ALS. It was observed that SOD1 aggregation
can trigger Ca2+ overload (Tradewell et al., 2011) and in turn,
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FIGURE 4 | Plasma derived MVs from ALS patients are enriched with pathological proteins compared to controls. (A) SOD1, TDP-43, and FUS detection by
Western Blot analysis in the soluble fraction of MVs and EXOs derived from plasma of 2 ALS and 2 healthy donors. Annexin V and Alix were used as marker control
for MVs and EXOs. SOD1, recognized by specific antibody 3H1 (but not by polyclonal antibody anti-SOD1) was present in MVs and EXOs of ALS patients compared
to healthy controls. TDP-43 bands and FUS were recognized in MVs and in EXOs. Images are cropped for clarity and full figures are shown in Supplementary
Figures 2–4; (B) TDP-43, p-TDP-43, SOD1, and FUS densitometric analysis in MVs and EXOs soluble fraction from 30 ALS patients and matched controls. (ANOVA
test, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗P < 0.001). ALS patients have an increased level of SOD1, TDP-43, FUS level in MVs compared to controls. No variation was
observed in EXOs of patients and controls; (C) SOD1 insoluble fraction in MVs and EXOs from 6 CTRLs and 6 ALS patients. Example of filter retardation assay
probed with polyclonal anti-SOD1 antibody (Santa Cruz Biotechnology, United States) and its Ponceau; (D) SOD1 densitometric analysis in MVs and EXOs insoluble
fraction from 22 ALS patients and matched controls. (ANOVA test, ∗∗P < 0.01). SOD1 protein level was not different between ALS and CTRLs group neither in MVs
and EXOs but the real difference was between EXOs and MVs, since the latter have less protein than the first.
that Ca2+ can bind to SOD1 promoting its aggregation (Estaìcio
et al., 2015). Deregulated Ca2+ levels can activate calpain protease
that cleaves TDP-43 at the C-terminal, generating aggregation
prone N-terminal segments that are found in the majority of
ALS patients (Aggad et al., 2014; Yamashita and Kwak, 2014).
Mutation of FUS protein leads to CAMK2N2 up-regulation
(Convertini et al., 2013), which phosphorylates AMPA receptors
inducing Ca2+ release. In summary, the literature can partially
explain how SOD1, TDP-43, and FUS can be transported in
MVs under pathological stresses, however, further studies are
needed.
To underline the impact of MVs on ALS diseases, we have
already demonstrated that leukocyte derived MVs (LMVs) are
able to transport pathological proteins like p-TDP-43 and in
particular SOD1. The regulation of LMVs formation might exert
a neuroprotective effect by SOD1 protein sequestration, which
have a significative impact on disease progression (Sproviero
et al., unpublished). In this study we demonstrated that MVs of
ALS patients are enriched with potentially pathological (SOD1,
TDP-43, p-TDP-43, FUS), compared to CTRLs while EXOs
do not show any protein changes, even if both types of EVs
have bigger size compared to controls. These two classes of
EVs are complex systems of scavengers and further studies are
needed to understand if lipids or RNA might enhance their
size. However, according to our previous study, these data
postulate that MVs can act as scavangers of toxic proteins, which
are known to be involved in prion-like distribution in ALS
disease.
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